Summary
Latest filing:
Jeffrey W. Chell is Director of Actinium Pharmaceuticals, Inc. (ATNM). 1 SEC Form 4 filing on record, dated 4 September 2026.
Recent Transactions
1Every recent SEC Form 4 transaction Jeffrey W. Chell has reported, most recent first.
Other Insiders Active in the Same Sector
No other insider has filed at Jeffrey W. Chell's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- KKR Phoenix Aggregator L.P. - $2.09B of BTSG open-market activity in the last 12 months
- KKR Group Partnership L.P. - $2.09B of BTSG open-market activity in the last 12 months
- Carlyle Group Inc. - $1.63B of MDLN open-market activity in the last 12 months
- Carlyle Mozart Coinvestment Holdings, L.P. - $1.63B of MDLN open-market activity in the last 12 months
- WARBURG PINCUS CO. - $1.12B of SHC open-market activity in the last 12 months
- CP Circle ML Holdco GP, LLC - $1.07B of MDLN open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Jeffrey W. Chell?
Jeffrey W. Chell is a corporate insider, tracked as Director of Actinium Pharmaceuticals, Inc. (ATNM). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Jeffrey W. Chell submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Where can I see all of Jeffrey W. Chell's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Jeffrey W. Chell and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
